Lung Cancer Surgery: Thoracoscopic Lobectomy And Wound Infection Rates Overview This meta-analysis rigorously examines the impact of thoracoscopic lobectomy on wound infection rates and complications among lung cancer patients. Through a comprehensive search across multiple databases, including PubMed, Embase, and Cochrane Library, among others, this study identified 21 relevant studies encompassing 2,118
Tag: lung cancer
Smoking And Mental Health After Lung Cancer Diagnosis
Smoking And Mental Health After Lung Cancer Diagnosis Overview This study investigated the emotional well-being, stigma experiences, and their connection to smoking history in individuals diagnosed with lung cancer. Analyzing data from 539 participants across various geographic locations from November 2019 to July 2022, the study utilized validated survey tools to assess
NSCLC First Line Therapy Chemotherapy Combinations
NSCLC First Line Therapy Chemotherapy Combinations Overview This retrospective study explores optimal first-line treatments for non-small cell lung cancer (NSCLC) patients with brain metastases (BMs) lacking driver gene alterations. The research compares the effectiveness of immunotherapy plus chemotherapy (ICI+Chemo) against bevacizumab plus chemotherapy (Beva+Chemo). The study, conducted between March 2017 and May
Colorectal Cancer: A Nomogram To Predict Metastases
Colorectal Cancer: A Nomogram To Predict Metastases Overview This study addresses the imperative task of identifying risk factors associated with distant metastasis in early-onset colorectal cancer (EOCRC), aiming to enhance understanding of its etiology and facilitate preventive treatments. The research, utilizing data from EOCRC patients in the SEER database (2010-2015), seeks to
lung cancer patients and pulmonary embolism risk factors
lung cancer patients and pulmonary embolism risk factors Overview Pulmonary embolism (PE) is a grave complication observed in individuals afflicted with lung cancer. This investigation aimed to ascertain the risk factors and evaluate the clinical attributes of advanced lung cancer patients who develop PE. In this research, a retrospective assessment was conducted on
Tislelizumab Treatment And Quality Of Life In Lung Cancer Patients
Tislelizumab Treatment And Quality Of Life In Lung Cancer Patients Overview In the Phase 3 trial RATIONALE-303 (NCT03358875), the study evaluated the health-related quality of life (HRQoL) among patients with advanced non-small cell lung cancer (NSCLC) who were treated with either tislelizumab or docetaxel. The assessment utilized three measurement instruments: EORTC QLQ-C30,
Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC
Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC Objectives To assess the effectiveness and safety of pembrolizumab monotherapy and in combination with chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC). Introduction Historically, patients with advanced NSCLC have a poor prognosis despite the use of platinum-based chemotherapy drugs. The 5-year relative survival rate of
Lung Cancer with Brain Metastasis After Late-Onset Bipolar Disorder: A Case Report
Lung Cancer with Brain Metastasis After Late-Onset Bipolar Disorder: A Case Report Background Bipolar disorder is a multifactorial illness with uncertain etiology and geriatric new-onset manic episodes are highly associated with secondary organic causes. The presented case demonstrates the importance of excluding secondary causes during the entire disease course. Overview Bipolar disorder is a
Anlotinib with Camrelizumab in Lung Cancer Treatment
Anlotinib with Camrelizumab in Lung Cancer Treatment Background Checkpoint inhibitors (CPIs) and anti-angiogenic agents are emerging as potential novel treatment choices for advanced cancers including metastatic non-small-cell lung cancer (NSCLC). However, the combination of these two standard therapies has not been investigated in third-line or further-line treatment of patients with advanced NSCLC.
Inoperable locally advanced non-small cell lung cancer: Survival rates of Endostar, CCRT
Inoperable locally advanced non-small cell lung cancer: Survival rates of Endostar, CCRT Inoperable locally advanced non-small cell lung cancer (NSCLC): An Introduction Accounting for approximately 80% of lung cancers, non-small cell lung cancer (NSCLC) is the most common subtype. Most NSCLC patients are diagnosed at an advanced stage with a mere 15-20%
